Algiax Pharmaceuticals is founding partner of the new Center of Competence for Innovative Diabetes Therapy (KomIT) funded by NRW and EU

New Center of Competence for Innovative Diabetes Therapy (KomIT) is funded by NRW and EU

Erkrath, Germany – Algiax Pharmaceuticals is part of a new consortium of eight partners from industry and academia focusing on the development of new diabetes therapies. During the next three years, a new Center of Competence will be established at the German Diabetes Center (DDZ) based on a total funding of about 3.5 Mio Euro provided by Northrhine-Westphalia and the EU. This center is coordinated by DDZ and aims at efficient translation of new research results into clinical application, finally improving therapeutic options for diabetic patients. Algiax has several preclinical drug candidates which have a great potential for further development as a new anti-diabetic therapy.
The continuous rise in the number of diabetic patients in Germany and the associated socio-economic burden for the health system urgently require the development of new causal therapies. "Together with our partners we aim to establish a sustainable infrastructure, to bring innovative approaches of diabetes therapy rapidly and directly to the patients" explains Prof. Michael Roden, scientific Director of the German Diabetes Center and coordinator of the new Center of Competence for Innovative Diabetes Therapy (KomIT). "Our joint activities aim to bundle expertise, finally leading to scientific and technological break-throughs in diabetes research". In addition to Algiax Pharmaceuticals and DDZ, the other partners are: LDC, Taros Chemicals GmbH & Co. KG, vivo Science GmbH, A & M Labor für Analytik und Metabolismusforschung Service GmbH, PROFIL Institut für Stoffwechselforschung GmbH, and TU Dortmund with the Drug Discovery Hub Dortmund (DDHD).

Algiax Pharmaceuticals (www.algiax.com) is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.
Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain. Algiax is currently preparing a Phase 2 study in subjects with chronic neuropathic pain after peripheral nerve injury.
Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterization. The main focus area for these novel compounds will be the treatment of Diabetes.
Algiax’ strategy is to develop its drug candidates up to a Clinical Phase II-III stage and out-license them to pharmaceutical and biotech companies for further clinical development and market authorization. For additional information, please visit www.algiax.com.

Algiax Pharmaceuticals GmbH
Dr. Ingo Lehrke, CEO
Max-Planck-Straße 15a
D-40699 Erkrath, Germany
ingo.lehrke@algiax.com

This release was published on openPR.